Capital alone is no longer the deciding factor for management teams evaluating potential GP partners, argued CEOs from Eurazeo, Astorg and Ridgepost at an industry event on Wednesday.
GPs must ensure portfolio company boards can answer diligence questions cleanly and quickly at a moment's notice, writes PwC partner Gregory Bournet.
The rapid growth of the secondaries market has led to suggestions that it could see transaction volumes of $500bn – or even $1trn – by 2030. Just four years out from this deadline, are such predictions realistic?
While a handful of pan-Asian mega-funds are soaking up the majority of LP interest, some argue that local mid-market champions are most likely to deliver outsized returns for investors in Asia-Pacific.
Disclosed healthcare buyout value fell to $51bn in H1 2026 from around $60bn a year earlier, with pressures from AI disruption and the Iran war contributing to the slowdown.
In today's edition, A $62bn pension is seeking leverage for liquidity; A sovereign wealth fund's PE allocation falls to a nine-year low – with a catch; Chinese PE activity rebounds.
The $37bn investment arm of Denmark’s Novo Nordisk Foundation is building a roster of homegrown GPs in Asia and growing its regional headcount, says managing partner Amit Kakar.
In today's edition, A $66 billion LP says sector selection should be left to the experts; Greater China PE gets a shot in the arm; LPs are supporting their GPs on climate issues.
As deploying capital gets harder, lenders and lawyers are turning to hybrid structures that blend sub-line mechanics with parallel vehicles and squeezing more leverage out of uncalled commitments.
The pressing need for more healthcare professionals globally is proving a tailwind for PE investors in medical education.